Search

Displaying results 2671 - 2680 of 5392 in total
  1. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascula...

  2. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. I...

  3. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-depen...

  4. Drug

    Fluspirilene

    go.drugbank.com/drugs/DB04842
    ApprovedWithdrawn

    A long-acting injectable antipsychotic agent used for chronic schizophrenia.

    Categories: Dopamine D2 Receptor Antagonists
  5. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

  6. Drug

    Hu-PHEC Liver

    go.drugbank.com/drugs/DB18347
    Experimental

    Hu-PHEC Liver is an adult hemogenic endothelial cells.

    Synonyms: Hu-PHEC Liver
  7. Drug

    Dequalinium

    go.drugbank.com/drugs/DB04209
    Approved

    Due to its flexible structure, dequalinium was investigated to build drug and gene delivery systems.

    Products: D-COOL
  8. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    [A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy.

  9. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907]

  10. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance.